Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3642506 | 0.86 | GRM5 (0.74) | GRM5CYP3A4LMNACYP1A2CYP2C9 | |
| SCHEMBL3644001 | 0.84 | GRM5 (0.69) | GRM5CYP3A4LMNACYP1A2CYP2C9 | |
| SCHEMBL3642809 | 0.84 | GRM5 (1.00) | GRM5CYP3A4LMNACYP1A2CYP2C9 | |
| SCHEMBL512907 | 0.83 | GRM5 (0.70) | GRM5CYP3A4LMNACYP1A2CYP2C9 | |
| SCHEMBL3637637 | 0.83 | GRM5 (1.00) | GRM5CYP3A4LMNACYP1A2CYP2C9 | |
| SCHEMBL3641798 | 0.82 | GRM5 (1.00) | GRM5CYP3A4LMNACYP1A2 | |
| SCHEMBL3645759 | 0.82 | GRM5 (0.86) | GRM5CYP3A4LMNACYP1A2CYP2C9 | |
| SCHEMBL3641430 | 0.82 | GRM5 (0.65) | GRM5CYP3A4LMNACYP1A2CYP2C9 | |
| SCHEMBL514159 | 0.82 | GRM5 (0.62) | GRM5CYP3A4LMNAALDH1A1MAPT | |
| SCHEMBL3644694 | 0.81 | GRM5 (0.84) | GRM5CYP3A4LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GRM5 2/4885CYP3A4 1085/4885LMNA 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.